Observation of the clinical effects of comprehensive treatment of middle and late ovarian cancer

Objective To observe and analyze the clinical efficacy of comprehensive treatment of middle and late ovarian cancer. MethodsA total of 60 middle and late ovarian cancer patients in our department were selected to undergo comprehensive treatment including tumor reductive surgery and chemotherapy before efficacy analysis. ResultsAfter comprehensive treatment, the 5-year survival rate was 50.00% for ovarian cancer patients at phase Ⅱ, and 47.50% for those at phase Ⅲ, without statistical difference (P>0.05). After tumor reductive surgery, the 5-year survival rate was 57.89% for patients without residual lesions, which was remarkably different from 31.82% for those with ≤ 1 cm residual lesions (P<0.05). Furthermore, the 5-year survival rate was 61.54% for middle and late ovarian cancer patients after 8 treatment durations of chemotherapy, which was remarkably different from 33.33% for those receiving chemotherapy less than 8 treatment durations (P<0.05). ConclusionsThere is no significant relationship between the efficacy of comprehensive treatment and the clinical stage of ovarian cancer. The residual lesions after tumor reductive surgery can greatly affect efficacy. Patients show a high 5-year survival rate after 8 treatment durations of chemotherapy.